Here are some numbers on what the distribution of the generic Eloxatin could amount for Caraco:
“If Sun launches at risk, our conservative assumptions suggest Sun could easily generate about $50 million in profits during the exclusivity window,” Macquarie analysts Abhishek Singhal and Gautam Duggad wrote in a report.
For ANDAs in the exclusivity window, Caraco gets 10% of the profits. The costs for Caraco should be minimal as Sun Pharma is responsible for production of the drugs. At 10% of the estimated $50 million, Caraco could end up netting $4-5 million. This is over a 6 month period. This should make Caraco break even or even cash positive.